"The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Bexsero is the second vaccine approved"...
ActHIB vaccine is contraindicated in children with a history of hypersensitivity to any component of the vaccine and to any component of Tripedia vaccine when it is used to reconstitute ActHIB. Any contraindication for Tripedia vaccine is a contraindication for TriHIBit vaccine, ActHIB vaccine reconstituted with Tripedia vaccine. (Refer to product insert for Tripedia vaccine.)
TriHIBit vaccine (ActHIB reconstituted with Tripedia) is contraindicated in children who have shown symptoms of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause. TriHIBit is contraindicated in children who have a progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy. Pertussis-containing vaccines should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/21/2014
Additional ActHIB Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.